Anorexia nervosa, a devastating eating disorder, has long puzzled researchers seeking effective treatments. While doctors can help restore nutrients and psychologists can reshape thought patterns, the high relapse rates among hospitalized patients highlight the need for deeper understanding. A recent study, presented by neuroscientist Virginie Tolle at the Federation of European Neuroscience Societies Forum 2026, offers a fascinating insight into the role of hormones in anorexia nervosa. The research, published in Translational Psychiatry, suggests that ghrelin, a hormone released when we're hungry, and its antagonist LEAP2 (liver-expressed antimicrobial peptide 2) may be key players in this complex disorder.
What makes this discovery particularly intriguing is the potential for early intervention. The study found that anorexia nervosa patients had higher levels of LEAP2 when first hospitalized, which decreased after four months of treatment and weight restoration. This suggests that LEAP2 could be a biomarker for relapse risk, allowing for potential early identification and targeted treatment.
The research also involved experiments on mice, which lost a quarter of their body weight. These mice exhibited increased impulsivity when offered an immediate food reward, a behavior that only partially subsided with refeeding. Higher LEAP2 levels strongly correlated with this impulsive behavior, suggesting a link between the hormone imbalance and the dangerous relapse cycles that make anorexia so challenging to recover from.
Tolle's findings are significant because they shed light on the metabolic signals that normally regulate hunger but seem to adapt differently in anorexia nervosa. This adaptation influences brain function and decision-making processes, potentially contributing to the disorder's persistence. The discovery of LEAP2 as a potential target for new therapeutic strategies is particularly exciting, as it opens up possibilities for developing pharmacological treatments to catalyze recovery.
However, it's essential to approach this research with a critical eye. While the study provides valuable insights, it's just the beginning. Larger-scale human trials are needed to replicate the findings and establish LEAP2 as a reliable biomarker. Additionally, the complex nature of anorexia nervosa means that a multifaceted approach, combining hormonal insights with psychological and nutritional interventions, will likely be necessary for effective treatment.
In conclusion, this study offers a promising direction for understanding and treating anorexia nervosa. By identifying LEAP2 as a potential biomarker and therapeutic target, researchers are taking a significant step forward in the quest for better recovery outcomes. However, the journey towards effective treatments is far from over, and continued research is essential to unlock the full potential of these findings.
